← Back to Screener
Sana Biotechnology, Inc. Common Stock (SANA)
Price$3.82
Favorite Metrics
Price vs S&P 500 (26W)-27.27%
Price vs S&P 500 (4W)3.69%
Market Capitalization$939.37M
All Metrics
Book Value / Share (Quarterly)$0.60
P/TBV (Annual)10.66x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.54
Price vs S&P 500 (YTD)-17.65%
EPS (TTM)$-0.98
10-Day Avg Trading Volume3.96M
EPS Excl Extra (TTM)$-0.98
EPS (Annual)$-0.96
ROI (Annual)-151.77%
Cash / Share (Quarterly)$0.52
ROA (Last FY)-58.57%
EBITD / Share (TTM)$-0.93
ROE (5Y Avg)-91.92%
Cash Flow / Share (Annual)$-0.54
P/B Ratio5.84x
P/B Ratio (Quarterly)6.74x
Net Income / Employee (Annual)$-2
ROA (TTM)-58.86%
EPS Incl Extra (Annual)$-0.96
Current Ratio (Annual)1.89x
Quick Ratio (Quarterly)1.81x
3-Month Avg Trading Volume3.11M
52-Week Price Return122.78%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.38
52-Week High$6.55
EPS Excl Extra (Annual)$-0.96
CapEx CAGR (5Y)-47.66%
26-Week Price Return-18.52%
Quick Ratio (Annual)1.81x
13-Week Price Return-25.74%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.89x
Enterprise Value$867.502
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.52
3-Month Return Std Dev72.37%
Net Income / Employee (TTM)$-2
ROE (Last FY)-151.77%
EPS Basic Excl Extra (Annual)$-0.96
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.98
ROI (TTM)-141.99%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.38
Price vs S&P 500 (52W)87.69%
Year-to-Date Return-13.51%
5-Day Price Return9.66%
EPS Normalized (Annual)$-0.96
ROA (5Y Avg)-45.24%
Month-to-Date Return22.22%
Cash Flow / Share (TTM)$-1.33
EBITD / Share (Annual)$-0.93
ROI (5Y Avg)-91.92%
EPS Basic Excl Extra (TTM)$-0.98
P/TBV (Quarterly)10.66x
P/B Ratio (Annual)6.74x
Book Value / Share (Annual)$0.60
Price vs S&P 500 (13W)-28.60%
Beta2.29x
Revenue / Share (TTM)$0.00
ROE (TTM)-141.99%
52-Week Low$1.53
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.27
4.27
4.27
4.27
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
SANASana Biotechnology, Inc. Common Stock | — | — | — | — | $3.82 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Sana Biotechnology develops engineered cell therapies to treat diseases across multiple therapeutic areas, including oncology, diabetes, B-cell-mediated autoimmune disorders, and central nervous system conditions. The company's pipeline includes several product candidates in development, addressing significant unmet medical needs in these high-value treatment markets.